Cargando…

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight million reports from the FDA Adverse Effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cohen, Isaac V., Makunts, Tigran, Atayee, Rabia, Abagyan, Ruben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431207/ https://www.ncbi.nlm.nih.gov/pubmed/28469132 http://dx.doi.org/10.1038/s41598-017-01590-x

Ejemplares similares

Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Cohen, Isaac V., et al.
Publicado: (2017)

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids
por: Makunts, Tigran, et al.
Publicado: (2019)

Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain
por: Makunts, Tigran, et al.
Publicado: (2018)

Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory
por: Makunts, Tigran, et al.
Publicado: (2019)

Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites
por: Makunts, Tigran, et al.
Publicado: (2020)

Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis
por: Makunts, Tigran, et al.
Publicado: (2019)

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database
por: Cohen, Isaac V., et al.
Publicado: (2021)

How can proton pump inhibitors damage central and peripheral nervous systems?
por: Makunts, Tigran, et al.
Publicado: (2020)

Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports
por: Cohen, Isaac V., et al.
Publicado: (2020)

Common osteoporosis drug associated with increased rates of depression and anxiety
por: Keshishi, Dro, et al.
Publicado: (2021)

Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data
por: Joulfayan, Haroutyun, et al.
Publicado: (2023)

Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events
por: Makunts, Tigran, et al.
Publicado: (2022)

Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety
por: Wollmer, M. Axel, et al.
Publicado: (2021)

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
por: Makunts, Tigran, et al.
Publicado: (2022)

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data
por: Makunts, Tigran, et al.
Publicado: (2021)

Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
por: Makunts, Tigran, et al.
Publicado: (2023)

Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
por: Nikkheslat, Naghmeh
Publicado: (2021)

Ketamine: stimulating antidepressant treatment?
por: Malhi, Gin S., et al.
Publicado: (2016)

Immunoregulation and antidepressant effect of ketamine
por: Zhang, Nan, et al.
Publicado: (2021)

The Ketamine Antidepressant Story: New Insights
por: Alshammari, Tahani K.
Publicado: (2020)

The role of dissociation in ketamine’s antidepressant effects
por: Ballard, Elizabeth D., et al.
Publicado: (2020)

The antidepressant properties of ketamine (literature review)
por: Chamsi, F. Z., et al.
Publicado: (2023)

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants
por: Browne, Caroline A., et al.
Publicado: (2013)

Ketamine as Antidepressant? Current State and Future Perspectives
por: Hasselmann, H. W.W.
Publicado: (2014)

Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?
por: Chaki, Shigeyuki
Publicado: (2017)

Structural Integrity in the Sustained Antidepressant Effect of Ketamine
por: Belujon, Pauline
Publicado: (2017)

Ketamine: a new chapter in antidepressant development
por: Zarate, Carlos A.
Publicado: (2020)

Antidepressants in the treatment of chronic headaches: therapy of psychiatric comorbidity or other mechanisms?
por: Pinessi, Lorenzo
Publicado: (2004)

Activation of σ1-Receptors by R-Ketamine May Enhance the Antidepressant Effect of S-Ketamine
por: Kalkman, Hans O.
Publicado: (2023)

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective
por: Hashimoto, Kenji
Publicado: (2019)

Astrocyte Specific Remodeling of Plasmalemmal Cholesterol Composition by Ketamine Indicates a New Mechanism of Antidepressant Action
por: Lasič, Eva, et al.
Publicado: (2019)

Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?
por: Thakurta, Rajarshi Guha, et al.
Publicado: (2012)

Acute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine
por: Chilukuri, Harihar, et al.
Publicado: (2014)

Antidepressant mechanism of ketamine: perspective from preclinical studies
por: Scheuing, Lisa, et al.
Publicado: (2015)

NMDAR inhibition-independent antidepressant actions of ketamine metabolites
por: Zanos, Panos, et al.
Publicado: (2016)

Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
por: Chaki, Shigeyuki
Publicado: (2017)

The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication
por: Andrashko, Veronika, et al.
Publicado: (2020)

Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
por: Xu, Songbai, et al.
Publicado: (2022)

Regulatory Clearance and Approval of Therapeutic Protocols of Transcranial Magnetic Stimulation for Psychiatric Disorders
por: Cotovio, Gonçalo, et al.
Publicado: (2023)

Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine’s antidepressant effects
por: Sydnor, Valerie J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_llh0mep30rg0450aj7sek7ul4m